Assemblywoman Patricia Egan Jones, D-5th District, on July 9 called for an investigation into Teva Pharmaceuticals and submitted testimony to Gov. Phil Murphy’s Task Force on the New Jersey Economic Development Authority’s Tax Incentive Program.
“It is inconceivable to me that New Jersey and Governor Murphy would give $40 million to a company to relocate to New Jersey where it has been documented that they are colluding and conspiring to sell opioids and other drugs that have killed tens of thousands, including perhaps thousands alone in New Jersey,” Jones said in a statement. “The value of the precious lives lost as a result of the drugs peddled by this company cannot be calculated.” Teva is moving its North American headquarters from Pennsylvania to Parsippany.
According to Jones, Teva paid $85 million to Oklahoma to settle charges arising from the opioid epidemic in that state, paid a $27 million fine for giving kickbacks to doctors who allegedly overprescribed medications to senior citizens, and agreed to pay a fine of more than $500 million to settle alleged violations of anti-bribery laws.
“Today, I am sending a letter to the Attorney General, the Comptroller and the U.S. Attorney asking for an immediate investigation with respect to Teva Pharmaceuticals and its tax credit application,” said Jones.
Murphy’s office told NJBIZ that in light of the announcement of the AG’s action against Teva earlier this year, the administration asked the EDA for a more thorough review of Teva’s application to ensure that all necessary disclosures were made at the time of the application and whether the more recent disclosures warranted an alteration or suspension of the award.
“We did this proactively. That review is ongoing,” a spokesperson said. “In addition, last month the EDA sent letters to Teva and several other companies requesting information on recent disclosures. That review also is ongoing.”